Overview of Dimefor

Property	Description
Active Ingredient	Metformin Hydrochloride (Metformin HCl)
Form	Oral Tablets (Immediate-Release and Extended-Release)
Pharmacological Class	Biguanide (Antihyperglycemic Agent)
Common Use	Foundational therapy for Type 2 Diabetes Mellitus
Origin	Synthetic

Dimefor: Identity and Classification

Dimefor is a prescription-only oral antidiabetic medication primarily used as a foundational therapy for the metabolic management of Type 2 Diabetes Mellitus. Its sole active substance is the synthetic compound Metformin Hydrochloride (Metformin HCl), which classifies the drug within the Biguanide pharmacological class. This classification is important because it confirms the drug works through a distinct, non-insulin-secretagogue mechanism. The medication is manufactured as Solid Oral Dosage Forms, specifically tablets, for oral consumption.

As an established trade name for Metformin HCl, Dimefor is clinically recognized for its efficacy in improving glucose metabolism in adult patients with Type 2 Diabetes. The regulatory approval of its active ingredient, Metformin, decades ago reinforces its authoritative standing as a preferred starting medication in diabetes care.

General Therapeutic Purpose

The general purpose of Dimefor is to achieve long-term glycemic control by directly lowering elevated blood sugar concentrations. It performs its potent antihyperglycemic effect by addressing the core issue of insulin resistance. It achieves this by focusing on three main actions: reducing glucose output from the liver and simultaneously improving glucose tolerance by making the body's peripheral cells more sensitive to existing insulin.

Research consistently demonstrates that Metformin is associated with medically significant improvements in long-term health outcomes for patients with Type 2 Diabetes, supporting its role as the widely accepted first-line therapy. For instance, it is typically used in a scenario where a patient requires assistance to stabilize blood sugar levels when diet and exercise alone are insufficient. Dimefor, as a single-ingredient product, delivers this essential therapeutic action using only Metformin HCl integrated into an oral matrix of solid excipients.

What side effects are possible with Dimefor?

Possible Side Effects and Safety Information

The safety profile for Dimefor (Metformin Hydrochloride) is officially structured by the frequency and nature of adverse reactions documented in regulatory sources.

Frequency-Classified Adverse Reactions

The most frequent adverse events are primarily related to the Gastrointestinal Disorders system. These effects are classified as Very Common, meaning they affect more than 1 in 10 patients. They include symptoms such as nausea, vomiting, diarrhoea, and abdominal pain. These disturbances are generally noted to be most frequent at the start of treatment and often diminish with continued use.

Adverse reactions classified as Common (affecting 1 to 10 out of every 100 patients) include taste disturbance and a decrease in serum Vitamin B12 concentrations, the latter being particularly associated with long-term use of the medication.

Serious Safety Considerations

A serious, but Very Rare (less than 1 in 10,000 patients), adverse reaction documented in official labeling is Lactic Acidosis. This condition is a severe metabolic complication that requires immediate attention.

Safety constraints tied to this risk include strict contraindications for use in patients with severe renal impairment or acute/severe hepatic impairment. Furthermore, the risk of Lactic Acidosis increases in the presence of acute or chronic alcohol consumption and necessitates temporary discontinuation when procedures involving iodinated contrast agents are performed.

Population-Specific Safety Notes

The official labeling mandates that renal function must be monitored prior to initiation and periodically during treatment, particularly in older adults, due to the heightened risk of Lactic Acidosis associated with decreased kidney function.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Dimefor (Metformin HCl)

Overdose Scope

Domain	Description
Documented overdose presentations:	Overdose or accumulation leads primarily to Lactic Acidosis, often preceded by non-specific symptoms including malaise, myalgias, increasing somnolence, respiratory distress, and abdominal distress. Severe acute overdose may also result in hypoglycemia.
Physiological systems affected (as stated in label):	Metabolic system (Acidosis), Cardiovascular system (Hypotension, Resistant Bradyarrhythmias), Central Nervous System (Somnolence, Coma).
Dose-related or exposure-related factors (if applicable):	Accumulation resulting in elevated plasma Metformin levels leads to toxicity.
Population-specific overdose notes (if applicable):	Risk of Lactic Acidosis is significantly increased in individuals with renal impairment, advanced age (ge 65 years), hepatic impairment, and acute hypoxic states.
Emergency-response statements (as written in official documents):	If Lactic Acidosis is suspected, the medicine must be immediately discontinued. General supportive measures must be instituted. Prompt hemodialysis is recommended for drug removal and acidosis correction.
When immediate medical help is required (label-derived phrasing only):	Lactic acidosis is a medical emergency that requires the patient to seek immediate medical attention and be treated in a hospital setting.

Overdose Classifications (High-Level)

Classification/Basis	Description
Severity classification (as defined in official documents):	Classified as life-threatening and fatal in approximately 50% of cases.
Regulatory basis (EMA / FDA / etc.):	Information is derived from official regulatory prescribing documents.
Overdose-context constraints (as defined in official documents):	No specific antidote is known. Management is supportive and procedural.

Resulting Overdose Structure

Official overdose statements:

Overdose presents as Lactic Acidosis, characterized by laboratory findings including elevated lactate levels and decreased blood pH.
Symptoms include non-specific manifestations such as malaise, myalgias, somnolence, and respiratory distress.
Severe outcomes documented are hypotension, hypothermia, resistant bradyarrhythmias, and death.
Immediate discontinuation of the medicine and treatment in a hospital setting are required, as Lactic Acidosis is a medical emergency.
Prompt hemodialysis is recommended as the necessary procedural intervention to remove the accumulated drug.

Connection to the overall overdose profile (2–4 sentences): Official regulatory documents define the overdose profile by the severe risk of Lactic Acidosis, mandating that any suspected symptom, regardless of initial presentation, constitutes a medical emergency. This requires individuals to seek immediate medical attention and triggers the need for prompt hemodialysis as the primary, regulator-documented management strategy for drug removal. The official structure emphasizes the life-threatening nature and the need for hospital-based procedural intervention.

Therapeutic Uses of Dimefor

What Dimefor Treats: Main Uses and Benefits

Dimefor (Metformin HCl) is an oral medicine applied across therapeutic domains related to metabolic health. Its use is commonly directed at managing symptoms related to systemic imbalance.

This medicine is commonly used to help manage Type 2 Diabetes Mellitus, addressing the chronic hyperglycemia that defines the condition. It supports the management of persistently elevated blood sugar levels, and contributes to the goal of reducing the risk of serious, long-term health complications, such as heart and kidney disease, associated with persistent systemic imbalance.

For individuals with Prediabetes who face a high risk of disease progression, its use may assist with therapeutic goals related to addressing risk factors associated with the development of Type 2 Diabetes. It is also relevant for women with Polycystic Ovary Syndrome (PCOS) to support the regulation of menstrual cycles and ovulation, which contributes to easing the symptom load related to endocrine and reproductive health.

Quick Fact: Relief for Metabolic Symptoms

Dimefor contributes to functional stability by supporting the body’s ability to manage elevated blood sugar levels, which supports general well-being and day-to-day comfort during periods of systemic imbalance.

Eligibility and Restrictions for Use

Dimefor (metformin) is authorized for use in adults and pediatric patients aged 10 years and older with certain eligibility restrictions based on specific clinical conditions.

Contraindicated Populations

The medicine is strictly contraindicated and must not be used by patients who have an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m^2, as this signifies severe renal impairment.

It is also forbidden for use in individuals with acute or chronic metabolic acidosis, including diabetic ketoacidosis, and those with a known hypersensitivity or allergic reaction to the drug or its components.

Use Restrictions and Limitations

Treatment should not be initiated in patients with an eGFR between 30 and 45 mL/min/1.73 m^2. Official documents recommend avoiding use in patients with clinical or laboratory evidence of hepatic impairment (liver disease) or a history of excessive alcohol intake.

Therapy must be temporarily discontinued for patients undergoing surgical procedures requiring restricted food and fluid intake or for radiologic studies involving intravascular administration of iodinated contrast materials. It should also be discontinued during acute conditions that may cause hypoxemia or a sudden decline in renal function, such as shock, sepsis, or acute heart failure.

Geriatric patients require more frequent monitoring of renal function due to the increased risk of reduced function with age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dimefor's interaction profile is primarily defined by agents that affect its elimination and those that share a risk of lactic acidosis.

Pharmacokinetic Interactions

Medicinal products that are inhibitors of the Organic Cation Transporter 2 (OCT2) can significantly increase the plasma concentration of Dimefor. Cimetidine is a specific example of an OCT2 inhibitor explicitly listed in regulatory documentation that necessitates caution and professional assessment when co-administered. The resulting elevated exposure may require dose adjustment by a healthcare provider, although specific dosing instructions are out of scope here.

Procedural and Pharmacodynamic Constraints

Iodinated Contrast Agents require a strict, temporary discontinuation of Dimefor at the time of or prior to the imaging procedure due to the additive risk of acute kidney injury and lactic acidosis. Dimefor may only be restarted a specified time after the procedure once renal function has been assessed as normal.

Other Agents Increasing Acidosis Risk

Co-administration with alcohol (ethanol) must be avoided as it potentiates the risk of lactic acidosis. Other agents, including carbonic anhydrase inhibitors (e.g., topiramate), diuretics, glucocorticoids, and sympathomimetics, may alter glucose control and necessitate increased monitoring of blood glucose levels.

Mechanism of Action

How Dimefor Works — Mechanism of Action

Dimefor (Metformin HCl) exerts its action primarily by influencing cellular energy metabolism in hepatocytes (liver cells). The mechanism begins with the drug's weak inhibition of Mitochondrial Respiratory Chain Complex I. This molecular interaction causes an increase in the AMP: ATP ratio, which subsequently leads to the allosteric activation of Adenosine Monophosphate-Activated Protein Kinase (AMPK). This AMPK activation suppresses the transcription and activity of key genes necessary for gluconeogenesis (new glucose synthesis).

The resulting decrease in hepatic glucose release is the primary physiological consequence. Systemic AMPK activation also extends to peripheral tissues, enhancing the translocation of GLUT4 transporters to muscle cell membranes. This process increases the efficiency of glucose utilization by peripheral tissues, thereby contributing to a reduction in circulating glucose concentration. A secondary action involves the inhibition of the SGLT1 transporter in the intestine, which modulates the rate of glucose transfer into the systemic circulation. The mechanism's full effect requires the presence of residual endogenous insulin, and its elimination is constrained by the kidneys.

Dosage and Administration Information

Instruction Map: How to use Dimefor — Official Administration Guidelines

This section outlines the official usage instructions for the drug Dimefor (metformin), based on official prescribing information and summaries of product characteristics.

Administration Scope

Instruction Entity	Official Instruction (Label-Based)
Route of Administration	Oral (by mouth) for all approved dosage forms (Immediate-Release and Extended-Release tablets/suspension).
Standard Adult Dosing	Initial Dose (IR): 500 mg twice daily or 850 mg once daily. Max Dose (IR): 2550 mg per day in divided doses. Max Dose (ER): 2000 mg once daily.
Timing in Relation to Meals	IR Tablets must be taken with meals. ER Tablets are typically administered once daily with the evening meal.
Age-Group Rules	Pediatric (Ages 10+): Starting dose is 500 mg twice daily with meals. Max dose is 2000 mg per day in divided doses.
Missed-Dose Rule	If a dose is missed, skip the missed dose and continue with the next dose at the regularly scheduled time. Do not double the dose.

Resulting Procedural Structure

Official documents structure the use of Dimefor into key procedural steps:

Kidney Function Assessment: Estimated glomerular filtration rate (eGFR) must be assessed prior to initiation of therapy. Use is contraindicated if eGFR is below 30 mL/min/1.73 m^2.
Dose Titration: Dosage is initiated at a low level and increased gradually (e.g., in 500 mg increments no sooner than every 1 to 2 weeks) to minimize gastrointestinal discomfort.
Tablet Integrity: Extended-release (ER) tablets must be swallowed whole and must not be crushed, split, or chewed, as this compromises the slow-release delivery mechanism.
Temporary Discontinuation: The medication must be temporarily discontinued at the time of, or prior to, certain medical procedures, such as iodinated contrast imaging studies or surgery involving general anesthesia. Reinitiation is contingent upon a stable re-evaluation of renal function after the procedure.

These instructions outline a protocol for drug use, mandating patient selection criteria (renal function), specific timing with food, and required adherence to administration constraints like swallowing tablets whole.

Recent Clinical Evidence

Recent Clinical Evidence / Overview of Studies

Efficacy in Musculoskeletal Pain

Acute Pain Studies: Clinical trials have investigated the tolerability profile in studies involving acute injuries like sprains. Studies examined the time to onset of change in pain scores in different patient groups.
- Study Design: Most research involved randomized, double-blind, placebo-controlled trials. The study design assessed whether pain levels were monitored over a 24-hour period.
Mechanism of Action Research: Research explored the molecular pathways involved. Other research focused on pathways that may be associated with changes in peripheral nerve sensitization.

Chronic Inflammation and Osteoarthritis

Long-Term Function: Studies explored whether this combination therapy was associated with changes in long-term function and patient-reported quality of life measures over a period of 12 months.
Inflammation Markers: Several studies evaluated whether the drug was associated with changes in inflammation and swelling markers, such as C-reactive protein (CRP) levels, in patients with chronic inflammatory conditions.

Safety Profile and Dosing Research

Dose-Finding Trials: Clinical trials evaluated the lowest doses tested to achieve the desired pharmacokinetic profile. These studies are critical for establishing the starting point for further efficacy research.
Renal and Hepatic Function: Studies assessed the pharmacokinetic profile in specific patient populations, including those with mild hepatic dysfunction. These studies focused on measuring drug clearance and metabolite levels.
Drug-Drug Interactions: Research examined potential interactions with grapefruit and certain anti-coagulant medications. Other research evaluated the drug against standard care concerning the risk of gastrointestinal adverse events.
Novel Formulations: Studies investigated the bioavailability of the new delivery method compared to the original tablet form, measuring drug concentration in the bloodstream over time.

Key Studies & References In Vitro and Clinical Evaluation of Drug-Drug Interaction Potential with Cytochrome P450 Inhibitors

Frequently Asked Questions (FAQ)

Common questions about Dimefor (FAQ)

Q: Is Dimefor the same kind of medicine as [similar drug name]?

Dimefor belongs to a specific family of medicines known as the Biguanide pharmacological class. Official information indicates that this class has a distinct mechanism of action compared to many other diabetes treatments. It works by acting primarily on the liver and improving the body's sensitivity to insulin, which helps lower blood sugar.

Q: Why did my doctor prescribe Dimefor instead of a different treatment?

Regulatory-backed documents describe the active ingredient in Dimefor (metformin) as the preferred initial drug (first-line therapy) for the management of Type 2 Diabetes Mellitus. This recommendation is based on its long-established efficacy in lowering blood glucose and its general tolerability profile.

Q: Are there any common foods or drinks I should avoid while using Dimefor?

Official documents state that alcohol (ethanol) should be avoided or limited due to the serious risk of lactic acidosis. While no specific foods are listed as forbidden, the medicine is recommended to be taken with meals. This is a common strategy to help reduce the gastrointestinal side effects that can occur when starting the medicine.

Q: How long can a person usually stay on Dimefor treatment?

Dimefor is intended for the long-term management of chronic conditions such as Type 2 Diabetes. Many people remain on the therapy for many years to maintain blood sugar control. Regulatory documents note that a decrease in Vitamin B12 concentrations is associated with long-term use, which requires monitoring by a healthcare provider.

Q: Is Dimefor safe to take if I have kidney issues?

Use of the medicine is subject to strict limitations based on kidney function. The official product information states that its use is contraindicated if a patient’s estimated glomerular filtration rate (eGFR) is below 30 mL/min/1.73 m^2. Initiation is also restricted if eGFR is between 30 and 45 mL/min/1.73 m^2.

Q: Can Dimefor be crushed or split if it's a tablet?

Official instructions state that the Extended-Release (ER) tablets must be swallowed whole and must not be crushed, split, or chewed, as this compromises the slow-release delivery mechanism. The Immediate-Release (IR) tablet form does not carry this specific instruction in its official labeling.

Q: What should I do if a side effect seems mild but doesn't go away?

Common side effects, such as gastrointestinal upset, are generally most frequent when starting therapy and often diminish with continued use and gradual dose increases. If a side effect is persistent, severe, or causes significant discomfort, patients are advised to consult with their healthcare provider.

Q: Do older adults react differently to Dimefor?

Official warnings note that older adults require more frequent monitoring of renal function during treatment. This is because reduced kidney function, which is more likely with age, increases the risk of the serious complication of Lactic Acidosis. This is a special consideration for monitoring.

Q: Can Dimefor interact with over-the-counter pain relievers?

Regulatory documents warn that agents that can potentially affect kidney function, such as certain non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, may increase the medicine's plasma concentrations. Since the medicine is cleared by the kidneys, this is a situation where careful medical supervision may be required.

Q: Why is Dimefor sometimes taken with food?

Regulatory guidelines state that Dimefor is administered with food primarily to minimize the common gastrointestinal side effects, such as nausea, diarrhea, and abdominal pain. Taking the medicine alongside a meal helps improve the body's tolerability during the initial phase of treatment.

Q: Are there any long-term side effects associated with Dimefor use?

The primary long-term side effect that is monitored is a decrease in serum Vitamin B12 concentrations, which is associated with extended use of the medicine. This condition may eventually lead to a deficiency and may require supplementation as determined by a healthcare provider.

Q: Is Dimefor safe for teenagers or young adults?

Dimefor is authorized for use in pediatric patients aged 10 years and older for the management of Type 2 Diabetes. This authorization, based on clinical evidence, sets the lower age limit for appropriate use according to official regulatory documentation.

Q: Are there different strengths of Dimefor tablets available?

Yes. The medicine is available in several strengths, including 500 mg and 850 mg Immediate-Release tablets and various strengths of Extended-Release tablets. This variety supports individualized dosing, which is determined by a healthcare provider.

Q: Does taking Dimefor affect the results of blood tests?

Yes. The medicine can cause a decrease in serum Vitamin B12 concentrations over long-term use. Furthermore, regulatory documents state that kidney and liver function tests, such as estimated glomerular filtration rate (eGFR), should be monitored periodically throughout treatment.

Q: Is Dimefor a widely prescribed medication?

The active ingredient in Dimefor, metformin, is described in authoritative sources as the first-line therapy for the management of Type 2 Diabetes Mellitus. Due to this official recommendation, it is one of the most widely prescribed medications globally in its therapeutic class.

Q: Do certain groups of people need a different dose of Dimefor?

Yes, dosage is highly individualized. Regulatory documents outline different starting and maximum doses for pediatric patients (age 10+) compared to adults. Additionally, dosage is always initiated at a low level and gradually adjusted (titrated) based on the patient's response and tolerability.

Q: What is the difference between an 'interaction' and a 'contraindication' for Dimefor?

A Contraindication is a strict medical condition, such as severe renal impairment, where the medicine must not be used because the risk is too high. An Interaction is a clinical situation where the effect of the medicine or another co-administered agent is altered, typically requiring close monitoring, temporary discontinuation, or a dose adjustment.

Q: Are there any specific warning signs I should look for when starting Dimefor?

Patients should be aware of the Very Common gastrointestinal effects (nausea, diarrhea, abdominal pain) that typically occur upon initiation. More importantly, symptoms of the Very Rare but serious complication of Lactic Acidosis (unusual tiredness, rapid breathing, severe muscle pain) should prompt immediate medical review.

Q: Can I take vitamins or minerals while using Dimefor?

The medicine is known to decrease Vitamin B12 levels over time, and a healthcare provider may recommend supplementation as determined by a healthcare provider. Regulatory documents do not contain general restrictions against taking common over-the-counter vitamins or minerals.

Q: Why is Dimefor restricted for people with certain health conditions?

Restrictions for conditions like severe kidney or liver impairment are imposed because these situations significantly increase the risk of developing a rare but very serious metabolic complication called Lactic Acidosis. These conditions compromise the body’s ability to clear the medicine, leading to accumulation and metabolic imbalance.

Q: Does Dimefor have known interactions with herbal products?

Official regulatory documents list specific drug-to-drug interactions but do not typically provide comprehensive guidance on general herbal or botanical products. It is important for patients to inform their healthcare provider about all products they are using, including supplements and herbal remedies.

Q: How quickly does Dimefor usually start working?

The drug begins working at the molecular level soon after the first dose. However, the full initial therapeutic effect of lowering blood sugar is typically reached when steady-state plasma concentrations are achieved, which occurs within 24 to 48 hours after starting the medicine.

Q: Does Dimefor cause weight changes, like gain or loss?

Official safety information indicates that the medicine is generally associated with weight stability or a modest weight loss over time. This profile is often considered a favorable aspect of the treatment when compared to some other medicines used for Type 2 Diabetes.

Q: Is it true that Dimefor is used for conditions other than its main use?

The official authorization for Dimefor is strictly for the management of Type 2 Diabetes Mellitus. Regulatory documents and official product information do not address or confirm uses outside of this approved indication.

Q: Can Dimefor affect my energy levels or make me feel tired?

Weakness or lack of energy is listed as an official adverse effect in the safety documents for the active ingredient. It is also an important symptom of the very rare, but serious, condition of Lactic Acidosis. If a patient experiences extreme or unusual tiredness, a healthcare provider should be consulted for review.

Q: Is Dimefor habit-forming or addictive?

According to authoritative medical sources, Dimefor is not classified as habit-forming or addictive. The medicine does not work on the brain's reward centers, and stopping the medicine should always be managed by a healthcare provider.

Q: Is Dimefor available as a generic medicine?

Yes. Dimefor is a trade name for the active ingredient Metformin Hydrochloride (Metformin HCl). Since the patent has expired on the active ingredient, generic versions of Metformin HCl tablets are widely available.

Q: Does Dimefor affect blood pressure or heart rate?

Dimefor is not classified as a blood pressure or heart medicine. However, an irregular or slow heartbeat is listed as a potential symptom associated with the rare but serious complication of Lactic Acidosis. Any heart-related symptoms are a serious concern and warrant immediate review by a healthcare provider.

Q: Is it normal to have a slight headache when first starting Dimefor?

Yes, official safety documents list headache as a common adverse reaction for the active ingredient. While common, any persistent, severe, or concerning symptom should be reviewed by a healthcare provider.

Q: What happens when I stop taking Dimefor?

Stopping the medicine without medical guidance will typically result in a loss of the therapeutic effect, causing elevated blood sugar levels to return. Cessation is typically managed under the supervision of a healthcare provider, who can adjust diet, exercise, or introduce alternative medications.

Q: Can Dimefor cause problems with sleeping or insomnia?

Changes in consciousness, such as somnolence (unusual sleepiness), are listed as a symptom associated with the rare, serious side effect of Lactic Acidosis. While insomnia is not typically listed as a common side effect, unusual sleepiness is a serious symptom that requires immediate medical review.

Q: Can I use Dimefor if I am currently trying to get pregnant?

Official guidelines recommend that women who are pregnant or planning to become pregnant should typically discontinue the medicine and discuss alternative management of their condition with a healthcare provider.

Q: How long do the effects of Dimefor last after taking it?

Official pharmacokinetic information states that the plasma half-life of the drug is approximately 6.2 hours for the Immediate-Release form. The Extended-Release (ER) formulation, however, is designed to release the medicine slowly and maintain therapeutic concentration over a full 24-hour period.

Q: Is it possible for Dimefor to stop working over time?

The medicine is designed for chronic use, but the underlying condition it treats is progressive. Regulatory documents indicate that some patients may eventually require an increase in dose or the addition of other medicines to maintain adequate blood sugar control over time.

Q: Is Dimefor considered a high-risk medication?

Dimefor is a widely used first-line therapy. However, it does carry a risk of a Very Rare but serious side effect called Lactic Acidosis. This is why its use requires strict adherence to monitoring protocols and contraindications related to kidney and liver function.

Q: How soon will I know if Dimefor is working for me?

While the medicine starts working quickly at a cellular level, the overall success of the therapy is officially evaluated by the healthcare provider over a period of two to three months. This involves measuring the HbA1c level, which is the key metric for long-term blood sugar control.

Q: Does Dimefor have an official patient information leaflet I can read?

Yes. All prescription medicines, including Dimefor, must provide an official Patient Information Leaflet (PIL) or FDA-approved Patient Labeling document. This leaflet summarizes the safety and usage information in patient-friendly terms and is provided by the regulatory authority.

How should Dimefor be stored and disposed of?

How to Store and Dispose of Dimefor (Metformin)

Official regulatory guidelines dictate specific requirements for storing and disposing of Dimefor to maintain its efficacy and safety.

Storage Conditions

Requirement	Official Statement
Temperature	Store at controlled room temperature, generally between 20 C and 25 C.
Protection	Keep away from excessive heat, light, and moisture (do not store in a bathroom).
Packaging	Keep the medicine in its original container, tightly closed.

Disposal and Safety

Requirement	Official Statement
Child Safety	Keep the medicine out of the reach and sight of children at all times.
Disposal Method	The preferred method is returning unused or expired medicine to a designated drug take-back program.
Prohibited Action	Do not flush the medicine down a toilet or pour it down a drain.

Dimefor